Neurocrine Biosciences (NBIX) Research & Development: 2010-2021
Historic Research & Development for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $92.7 million.
- Neurocrine Biosciences' Research & Development rose 34.15% to $92.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $309.8 million, marking a year-over-year increase of 22.16%. This contributed to the annual value of $160.5 million for FY2018, which is 31.76% up from last year.
- Neurocrine Biosciences' Research & Development amounted to $92.7 million in Q3 2021, which was up 23.93% from $74.8 million recorded in Q2 2021.
- Neurocrine Biosciences' Research & Development's 5-year high stood at $92.7 million during Q3 2021, with a 5-year trough of $21.9 million in Q2 2017.
- Over the past 3 years, Neurocrine Biosciences' median Research & Development value was $69.1 million (recorded in 2020), while the average stood at $66.0 million.
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 117.05% in 2017, then dropped by 23.08% in 2019.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Research & Development stood at $25.6 million in 2017, then spiked by 52.68% to $39.1 million in 2018, then increased by 27.67% to $45.3 million in 2019, then skyrocketed by 52.54% to $69.1 million in 2020, then skyrocketed by 34.15% to $92.7 million in 2021.
- Its Research & Development stands at $92.7 million for Q3 2021, versus $74.8 million for Q2 2021 and $73.2 million for Q1 2021.